Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | MOK | Q9UQ07 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905202 | 0.85 | KCNH2 (0.52) | ACP1JAK2MOKDYRK1AKCNH2 | |
| SCHEMBL15919372 | 0.83 | MOK (0.54) | ACP1MOKDYRK1AKCNH2 | |
| SCHEMBL15905232 | 0.79 | ACP1 (0.41) | ACP1JAK2MOKDYRK1AKCNH2 | |
| SCHEMBL3713224 | 0.77 | JAK2 (0.41) | HRH3JAK2 | |
| SCHEMBL15919600 | 0.77 | KCNH2 (0.56) | ACP1JAK2MOKDYRK1AKCNH2 | |
| SCHEMBL3713020 | 0.76 | PIK3CD (0.41) | DYRK1A | |
| SCHEMBL3714490 | 0.76 | HRH3 (0.47) | HRH3JAK2DYRK1A | |
| SCHEMBL15919703 | 0.75 | ACHE (0.41) | — | |
| SCHEMBL15919375 | 0.75 | MOK (0.45) | ACP1MOKKCNH2 | |
| SCHEMBL3721164 | 0.74 | PARP1 (0.47) | HRH3JAK2MOKKCNH2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ACP1 2825/4885HRH3 4559/4885JAK2 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.